Drug Profile
Docetaxel - AbbVie
Alternative Names: Docetaxel ActavisLatest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator Actavis
- Developer AbbVie
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Adenocarcinoma; Breast cancer; Head and neck cancer; Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie